UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 4, 2017
ACELRX PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
DELAWARE 001-35068 41-2193603
(State of incorporation) (Commission File No.) (IRS Employer Identification No.)
351 Galveston Drive
Redwood City, CA 94063
(Address of principal executive offices and zip code)


Registrant's telephone number, including area code: (650) 216-3500

ACELRX PHARMACEUTICALS INC

Form 8-K

December 04, 2017

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):



Item 7.01. Regulation FD Disclosure.

AcelRx Pharmaceuticals, Inc. (the "Company" or "AcelRx") will participate in various meetings with securities analysts and investors on Monday, December 4, 2017, and will utilize a presentation during those meetings. The presentation is furnished as Exhibit 99.1 to this Current Report and is incorporated herein by reference. The presentation will also be made available in the "Investor Relations" section of AcelRx Pharmaceuticals, Inc.'s website, located at www.acelrx.com.

The information contained in this Item 7.01 and in the accompanying Exhibit 99.1 to this Current Report shall be deemed to be "furnished" and shall not be deemed to be "filed" for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act. The information contained in this Item 7.01 and in the accompanying Exhibit 99.1 to this Current Report shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission under the Securities Act or the Exchange Act made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit

Number Description

99.1 <u>Slide presentation entitled, "Corporate Overview December 2017"</u>

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: December 4, 2017 ACELRX PHARMACEUTICALS, INC.

/s/ Raffi By: Asadorian

Raffi Asadorian Chief Financial Officer